Lv1
30 积分 2025-09-16 加入
Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors
22小时前
待确认
Overview of tumor immunotherapy based on approved drugs
23小时前
已完结
MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors
1个月前
已完结
Mechanotransduction and epigenetic modulations of chromatin: Role of mechanical signals in gene regulation
2个月前
已完结
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
3个月前
已完结
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
3个月前
已完结
Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries
3个月前
已完结
Predictors of sentinel lymph node metastasis in very thin invasive melanomas
4个月前
已完结
Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study
4个月前
已完结
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
4个月前
已完结
皖公网安备34019202002308
